Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation. by Mai, Hoa Le et al.
UC Davis
UC Davis Previously Published Works
Title
Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte 
Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation.
Permalink
https://escholarship.org/uc/item/7mv9m7h7
Journal
Transplantation direct, 4(4)
ISSN
2373-8731
Authors
Mai, Hoa Le
Treilhaud, Michèle
Ben-Arye, Shani Leviatan
et al.
Publication Date
2018-04-01
DOI
10.1097/txd.0000000000000772
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
KidneyTransplantationPoor Patient and Graft Outcome After Induction
Treatment by Antithymocyte Globulin in
Recipients of a Kidney Graft After Nonrenal
Organ Transplantation
Hoa LeMai, PhD,1,2 Michèle Treilhaud, MD,3 Shani Leviatan Ben-Arye, PhD,4 Hai Yu, PhD,5 Hélène Perreault, PhD,6
Evelyn Ang, PhD,6 Katy Trébern-Launay, PhD,1,2 Julie Laurent, PhD,7 Stéphanie Malard-Castagnet, PhD,8
Anne Cesbron, MD,8 Thi Van Ha Nguyen, PhD,1,2 Sophie Brouard, PhD,1,2 Lionel Rostaing, MD,9
Pauline Houssel-Debry, MD,10 Christophe Legendre, MD,11 Sophie Girerd, MD,12 Michèle Kessler, MD,12
Emmanuel Morelon, MD,13 Antoine Sicard, MD,13 Valérie Garrigue, MD,14 Georges Karam, MD,2 Xi Chen, PhD,5
Magali Giral, MD,1,2 Vered Padler-Karavani, PhD,4 and Jean Paul Soulillou, MD1,2Re
Ac
1
Un
2 I
3 U
4 D
5 D
6 D
7 M
8
du
9 D
To
10
11
De
12
Na
13
He
TrBackground. End-stage renal failure occurs in a substantial number of patients having received a nonrenal transplantation
(NRT), for whom a kidney transplantation is needed. The medical strategy regarding the use of immunosuppression (IS) for a kid-
ney graft in patients after an NRT is not well established. The prekidney grafts long-term IS advocates for a mild induction, such as
using anti-IL-2R antibodies, whereas addition of new incompatibilities and anti-HLA preimmunization may suggest using stronger
IS such as induction by polyclonal antithymocyte globulins (ATG). Methods. We performed Cox multivariate and propensity
score analysis of our validated transplant database to study the impact of the type of induction therapy on kidney graft survival
of recipients of a kidney graft after NRT. Results.We report here that kidney transplantation after NRT treated with an ATG in-
duction has a poorer outcome (kidney and recipient survival) than that with an anti–IL-2R induction. After accounting for potential
baseline differences with a multivariate Cox model, or by adjusting on a propensity score, we found that despite patients having
received ATG cumulate more risk factors, ATG appears independently involved. As animal-derived biotherapeutics induce
antiglycan antibodies and particularly anti–N-glycolylneuraminic acid (Neu5Gc) IgGswhichmay activate endothelial cells in patients
and grafts, we also investigated themagnitude and the nature of the anti-Neu5Gc elicited by the induction and showed that induc-
tion was associated with a shift in anti-Neu5Gc IgG repertoire. Possible reasons and mechanisms of a deleterious ATG usage in
these patients are discussed. Conclusions.Our study suggests that ATG induction after a kidney transplantation in recipients
already under maintenance IS for a NRTshould be used cautiously.
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FIGURE 1. Patient flowchart.
2 Transplantation DIRECT ■ 2018 www.transplantationdirect.comTransplantation of nonrenal solid organs, such as theheart, lung, or liver, is vital for patients with end-stage
failure of the respective organs, but may be complicated by
end-stage renal disease (ESRD) due to multifactorial causes.
Ojo et al1 have shown that 16.5% of nonrenal transplanta-
tion (NRT) recipients developed chronic renal failure (CRF)
over a median follow-up of 3 years, and that nearly one third
of these CRF patients already reached ESRD necessitating di-
alysis or transplantation. Occurrence of CRF in NRT patients
increased 4.5 times the risk of death and kidney transplanta-
tion for ESRD was associated with a significantly lower
5-year risk of death than dialysis. Thanks to the improved
care, NRT recipients now live longer, as a result, they have
more time to develop ESRD and to become an emerging
subpopulation of kidney transplant patients.2
However, little is known about the suitable treatment and
particularly the optimal type of induction forNRT patients at
the time of kidney transplantation. Because all these recipi-
ents are receiving combined immunosuppressive mainte-
nance treatment for their NRT, it is unclear whether they
also need a superimposed induction therapy for kidney trans-
plantation and, if so, which type of induction therapy would
be suitable. Some centers prefer induction with lympho-
depleting antibodies, such as antithymocyte globulin (ATG),3
or alemtuzumab4 to ensure sufficient immunosuppression
(IS) for the kidney allografts,whereas others opt for a nondeplet-
ing anti–IL-2R monoclonal antibody. A single-center retrospec-
tive study reported that induction therapy by alemtuzumab in
kidney transplantation recipients after NRT was associated
with lower acute rejection rate.4 However, another study an-
alyzing the United Network for Organ Sharing database
showed that induction therapy with either depleting or
non-depleting antibodies was not associated with improved
patient survival and even yielded inferior survival of kidney
recipients after liver transplantation.5 In fact, there is an ex-
treme paucity of literature regarding the impact of induction
treatment on kidney graft outcome after NRT.
In this report, based on our multicenter validated données
Informatisées et VAlidées en Transplantation (DIVAT) regis-
try database (www.divat.fr), we identified 128 recipients of
kidney transplant after NRT. The aim of our study was to de-
termine whether induction therapy with ATG or anti–IL-2R
at the time of kidney transplantation affects the kidney graft
and patients survival. After accounting for potential baseline
differences with amultivariate Coxmodel, or by adjusting on
a propensity score we found that, despite patients having re-
ceived ATG cumulate more risk factors, ATG appears indepen-
dently involved in the lower graft andpatient survival after ATG
induction. In addition, because animal-derived bio-therapeutics
such as ATG are immunogenic and can induce anti-anti–N-
glycolylneuraminic acid (Neu5Gc) antibodies6,7 which are able
to react with patient and graft endothelial cells,8 we also mea-
sured the levels and repertoire of anti-Neu5Gc IgG antibodies
in the serumof a small subgroupof patients after induction after
the kidney transplantation.
PATIENTS AND METHODS
Patients
Study Design
This is a retrospective analysis of the outcome of kidney
grafts after NRT using data extracted from the DIVATdatabase (see http://www.divat.fr), a registered and validated
database of solid organ transplant recipients from French
university hospitals including Lyon, Montpellier, Nancy,
Nantes, and Necker (Paris). We included 140 adult patients
(≥18 years old) who underwent a kidney transplant between
January 1, 1997, andDecember 31, 2013, after having previ-
ously received at least one of the after NRT: heart, liver, or
lung. Twelve patients without induction therapy at the time
of kidney transplant were excluded from the study due to
their small number. Of the remaining 128 patients (Figure 1),
72 received ATG (thymoglobulin, Genzyme) and 56 received
anti-IL-2R (54 basiliximab and 2 daclizumab). The indication
of ATG in this specific clinical situation differed among the
participating groups: 1 center gave ATG in all such patients
and other centers used ATG only when the recipients were
preimmunized. However, as shown latter in Table 1, the
protocols could not be follow in a substantial number of
patients indicating that other clinical criteria were taken
into account. The endpoint of our study was kidney graft
survival noncensored for death (hereinafter referred to as graft
survival), calculated from the date of kidney transplantation
to the date of return to chronic dialysis or death with a
functioning kidney graft, the latter was thus also considered
as graft loss.9Statistical Comparison of Graft Outcome
Continuous variables were compared using the t test. Cat-
egorical variables were compared using the χ2 test or Fisher
exact test whenever appropriate. Kaplan-Meier survival
curves were created and the log-rank test was used to study
the impact of each of the following variables on kidney graft
survival: donor age, donor type, cold ischemia time, recipient
age and sex, year of kidney graft, time from NRT to kidney
graft, time on dialysis before kidney graft, anticlass I and/or
class II HLA antibodies (Abs), recipient cytomegalovirus
(CMV) and hepatitis C virus (HCV) status, type of NRT, in-
duction type (ATG or anti–IL-2R) for NRT and the kidney
graft, type of maintenance treatment (calcineurin inhibitors,
mycophenolate mofetil or azathioprine, and corticosteroids),
and occurrence of acute rejection (intended to treat). A Cox
univariate analysis was done for each of the aforementioned
variables to calculate the hazard ratio (HR) as well as the
95% confidence interval (95% CI). Next, a Cox regression
TABLE 1.
Recipient and donor characteristics of kidney after NRT according to type of induction therapy
Variables
Total ATG Anti-IL-2R
P(n = 128) (n = 72) (n = 56)
Kidney donor
Agea 49.2 (3-79) 49.6 (3-76) 48.6 (4-79) 0.73
Deceased donor, n (%) 111 (87) 66 (92) 45 (80) 0.071
Cold ischemia time,a h 18.1 (0.2-41.2) 18.7 (0.2-41.2) 17.3 (0.3-39) 0.41
Recipient
NRT type
Heart, n (%) 61 (47.7) 37 (51.4) 24 (42.9) 0.37
Heart-lung, n (%) 14 (10.9) 3 (4.2) 11 (19.6) 0.008
Lung, n (%) 16 (12.5) 3 (4.2) 13 (23.2) 0.002
Liver, n (%) 37 (28.9) 29 (40.3) 8 (14.3) 0.0015
Age at kidney grafta 49.8 (18–74) 52.3 (22–71) 46.7 (18–74) 0.034
Male, n (%) 91 (71) 51 (71) 40 (71) 1.0
Kidney graft ≤ 2008, n (%) 67 (52) 39 (54) 28 (50) 0.72
Time from NRT to kidney graft,a y 10.3 (1–28) 10.6 (1–24) 9.9 (1–28) 0.49
Time on dialysis,a y 2.1 (0–16.4) 2.5 (0.01-10.6) 2.5 (0.03-16.4) 0.98
Anti-HLA class I pos, n (%) 33 (26) 20 (28) 13 (23) 0.68
Anti-HLA class IIb pos, n (%) 41 (34) 30 (43) 11 (21) 0.012
Combined anti-HLA class I/IIb 0.029
Either class I or II pos, n (%) 53 (43.4) 36 (52) 17 (32)
Both class I and II neg, n (%) 69 (56.6) 33 (48) 36 (68)
CMV pos, n (%) 78 (61) 52 (72) 26 (46) 0.004
HCV pos, n (%) 11 (9) 7 (10) 4 (7) 0.75
Maintenance treatment
CNIs, n (%) 125 (98) 71 (99) 54 (96) 0.58
Tacrolimus, n (%) 72 (56) 41 (57) 31 (55) 0.86
MMF, n (%) 114 (89) 63 (88) 51 (91) 0.58
Azathioprine, n (%) 9 (7) 6 (8) 3 (5) 0.73
Corticosteroids, n (%) 122 (95) 72 (100) 50 (89) 0.006
a Continuous variables (age and time) are reported as mean (range).
b Missing data for anti-class II in 6 patients (3 in each group).
CNIs, calcineurin inhibitors; MMF, mycophenolate mofetil; neg, negative; pos, positive.
© 2018 Wolters Kluwer Mai et al 3multivariate analysis was performed including predefined
clinically relevant variables: type of induction, recipient and
donor age, donor type, type of NRT and of their induction,
anti–class I and/or class II-HLA Abs, year of kidney graft,
presence of acute rejection and of other variables potentially
associated with kidney graft survival in the univariate analy-
sis (P ≤ 0.20 in the log-rank test of Kaplan-Meier estimates).
Then, a reduced model containing only significantly and inde-
pendently variables associatedwith kidney graft survival was ob-
tained using a backward procedure. Finally, to better assess
baselinedifferences betweenATGandanti–IL-2Rsubjects, amul-
tivariate logistic regression model was generated to estimate a
propensity score to receive ATG for each patient. All covariates
were predefined clinically relevant variables as well as variables
associated with ATG in the univariate analysis remaining signifi-
cantly and independently associated with ATG after a backward
analysis. The model performance was appreciated with the χ2-
Hosmer-Lemeshow and the c-statistic tests. P values less than
0.05 were considered to be statistically significant. Analyses
were performed usingR version 3.2.0. The statistical analysis
was subcontracted to Methodomics, Toulouse, France.
Measurement of Anti-Neu5Gc andAnti- Gal IgG by ELISA
anti-Neu5Gc IgG levels weremeasured usingmouse serum
proteins as coating antigens as previously described.10Details are given in supplementary materials and methods,
http://links.lww.com/TXD/A75.
Sialoglycan Microarray
Arrays were prepared on epoxy slides, then developed and
analyzed as previously described.10 Details of the assay are
also described in supplementary material and methods,
http://links.lww.com/TXD/A75.
Analysis of Neu5Gc in Basiliximab (Simulect) and ATG
by Mass Spectrometry
Simulect and ATG (100 μg each) was reduced with di-
thiothreitol (Sigma-Aldrich), alkylated with iodoacetamide
(Sigma-Aldrich), and digested with trypsin (4 μg, Promega).11
Glycopeptides were enriched from the digestion mixtures
using ProteoExtract kits (EMDMillipore).Mass spectrometry
analyses of the glycopeptides were performed on an
UltrafleXtreme mass spectrometer (Bruker Daltonics) with
dihydroxy benzoic acid (DHB; Sigma-Aldrich) as the matrix.RESULTS
Patient Characteristics
Compared with the anti-IL-2R group, the ATG group re-
cipients were older and more patients had anti-HLA class II
4 Transplantation DIRECT ■ 2018 www.transplantationdirect.comantibodies and a CMV-positive serology, and had received a
corticosteroid maintenance treatment. There were more liver
transplant in the ATG group and more lung and heart-lung
transplant in the anti–IL-2R group. Other recipient and do-
nor characteristics were not different between the 2 groups
(Table 1). To further evaluate the differences in demographics
between the 2 groups, Cohen d was also calculated for all the
continuous variables. Only recipient age at kidney graft
showed a small effect size with a Cohen d of 0.38, for other
continuous variables (donor age, cold ischemia time, time
from NRT to kidney graft, and time from dialysis), the
Cohen d coefficients were very small (0.06, 0.15, 0.12, and
0.003, respectively), which means that there were no major
differences in these demographic characteristics. As indicated
above, 4 of 5 participating centers were supposed to use
ATG only in kidney recipients with immunological risks,
particularly those with positive anti-HLA Abs. However, this
general rule was not strictly applied, and the preestablished
protocols of the induction therapy were often modified by
the transplant physician at the time of kidney transplantation.
Consequently, as shown in Table 1, half of patients who
received ATG had no anti-HLA Abs. On the contrary, one-
third patients who received anti-IL-2R had either anti-class
I or anti-class II Abs. As shown below, the impact of anti-
HLA Abs on graft survival was analyzed by univariate as
well as multivariate Cox model.TABLE 2.
Univariate analysis of kidney graft loss
Variables HR
Kidney donor
Age ≥55 y 2.18
Deceased donor 5.6
Cold ischemia time ≥ 20 h 0.7
Recipient
NRT type
Heart 1
Heart-lung (vs heart) 0.49
Lung (vs heart) 1.07
Liver (vs heart) 1.18
ATG induction (vs no ATG) for NRT
Age at kidney graft 1.01
Male 1.21
Kidney graft > 2008 1.09
Time from NRT to kidney graft ≥ 10 y 1.16
Time on dialysis ≥ 2 y 1.88
Anti-HLA class I pos 1.71
Anti-HLA class II pos 1.21
Either class I or II pos (vs both class I and II neg) 1.49
CMV pos 1.46
HCV pos 0.75
ATG induction (vs anti-IL-2R induction) for kidney graft 3.27
Maintenance treatment
CNIs 0.18
Tacrolimus 1.1
MMF 1.48
Azathioprine 0.95
Corticosteroids 1.95
Acute rejection 1.25Graft and Patient Outcome
During the follow-up period of the study, 39 patients
reached the endpoint, including 12 who returned to chronic
dialysis and 27 deaths. Univariate analysis of variables in re-
lation to graft survival was performed by log-rank test of
KaplanMeier estimates aswell as byCox univariate analysis.
As shown in Table 2, donors of 55 years or older and receiving
ATG induction therapy (vs anti-IL-2R induction) were signifi-
cantly associatedwith an increased risk of return to chronic di-
alysis or death (HR, 2.18 and 3.27; 95% CI, 1.14-4.17 and
1.49-7.17, and P Cox = 0.018 and 0.003, respectively).
Figure 2 shows the Kaplan-Meier survival curve comparing
the groups with ATG and anti–IL-2R induction (P = 0.002,
log rank test). As some kidney recipients received ATG induc-
tion years before anti–IL-2R antibodies were available, a com-
parison restricted to the grafts performed on overlapping years
was also done and showed a significant difference (P < 0.032)
of roughly the same magnitude (Figure S1 http://links.lww.
com/TXD/A69). A separate assessment of death and graft sur-
vival censored for death (Figure S2A and S2B http://links.lww.
com/TXD/A70) also showed that ATG treatment was signifi-
cantly associated with poor survival. The type of induction
treatment (ATG, anti-IL-2R, or no induction) or the previous
NRT/NRT type (heart or liver) had no significant influence
on graft survival. Next, the multivariate Cox regressionmodel
showed that ATG induction treatment was the only variable95% CI P, Cox P, log-rank
1.14-4.17 0.018 0.016
0.77-40.9 0.089 0.055
0.35-1.39 0.303 0.3
0.605
0.15-1.67 0.255
0.36-3.15 0.907
0.55-2.54 0.67
0.94
0.99-1.04 0.179
0.55-2.67 0.644 0.643
0.5-2.38 0.832 0.832
0.62-2.19 0.641 0.641
0.97-3.66 0.063 0.059
0.86-3.39 0.127 0.122
0.6-2.47 0.593 0.593
0.76-2.91 0.242 0.239
0.76-2.83 0.26 0.257
0.26-2.15 0.59 0.589
1.49-7.17 0.003 0.002
0.02-1.46 0.109 0.072
0.57-2.11 0.778 0.778
0.56-3.87 0.427 0.424
0.33-2.7 0.92 0.92
0.27-14.25 0.511 0.503
0.52-3.02 0.616 0.615
FIGURE 2. Kaplan-Meier estimate of graft survival (noncensored for
death). ATG inductionwasassociatedwith significantly lower kidneygraft
survival compared with anti-IL-2R induction (P = 0.0017, log-rank test).
© 2018 Wolters Kluwer Mai et al 5remaining significantly and independently associatedwith kid-
ney graft survival (Table 3). Antithymocyte globulin induction
was indeed associated with a 3.33-fold increase in the risk of
return to dialysis or death compared to anti–IL-2R induction
(95% CI, 1.44-7.70; P = 0.005). Donors 55 years or older
and deceased donors showed a nonsignificant tendency to be
associated with a lower graft survival (P = 0.067 and 0.057,
respectively). The presence of either anti–class I or anti–class
II HLA Abs (vs the absence of both) and the presence of at
least 1 acute rejection episode were not associated with lower
graft survival (P = 0.40 and 0.38, respectively).
Because of the difference in distribution of variables in the
2 groups, a propensity score to receive ATG (vs anti–IL-2R),
including recipient age, year of kidney graft, presence of class
II anti-HLA antibodies and recipient CMV status was also
applied. The performance of the propensity score was satis-
factory: the c-statistic for the logistic regression model was
0.77 (95% CI, 0.69-0.85) and the χ2-Hosmer-LemeshowTABLE 3.
Cox multivariate analysis of kidney graft loss
Variable Reference category
ATG induction (for kidney graft) Anti–IL-2R induction
Recipient age
Donor age ≥ 55 yr <55 yr
Deceased donor Live donor
NRT: heart-lung Heart
NRT: lung Heart
NRT: liver Heart
Anti-HLA: either class I or II pos Both class I and II neg
Year of kidney graft > 2008 ≤2008
Acute rejection No
Dialysis time ≥ 2 yr <2 y
CNI treatment No
Reduced Cox modela
ATG induction Anti–IL-2R induction
Donor age ≥ 55 yr <55 y
CNI treatment No
Cox model adjusted on the propensity scoreb
ATG induction Anti–IL-2R induction
aThe reduced model containing only significantly and independently variables associated with kidney graft
bPropensity score to receive ATG (vs anti–IL-2R) included recipient age, year of kidney graft, the presencestatistic model reached 0.85. The ATG treatment was con-
firmed to associate with poor prognosis in terms of return
to dialysis or death by the propensity score method (HR,
3.22; 95% CI, 1.30-7.95, P = 0.011), showing that despite
differences in giving ATG instead of anti-IL-2R at baseline,
there is a significant and independent effect of the induction
treatment contributing to the graft survival.
Complications and Causes of Death
To investigate whether patients having received ATG were
clinically overimmunosuppressed compared with those
treated by anti-IL-2R, we analyzed the incidence of infectious
and neoplastic complications after kidney transplantation
and the frequency of acute rejection. We found no difference
in global incidence of CMV, HSV, and VZV viral infections,
in severe infections (including sepsis, urinary tract infection,
and pneumonia/lung abscess), nor malignancies, between
the 2 groups (Figure S3A, S3B, and S3C http://links.lww.
com/TXD/A71). Acute rejection episodes presented the nonsig-
nificant trend to be higher in the ATG group: 21% in the ATG,
versus 9% in the anti-IL-2R induction group (P = 0.068)
(Figure S2C, http://links.lww.com/TXD/A70).
The main causes of death (Table 4) were as follows:
infection (7), cancer (3), chronic rejection of the NRT (3),
cardiac diseases (5), stroke (2), mesenteric infarction (1),
hepatic failure (2), and others (4). Despite a trend, there was
no significant difference in cardiovascular complications leading
or not to death in the ATG group (Figure S3D, http://links.lww.
com/TXD/A71). In addition, compared with other NRTs, a
prior heart transplant was not associated with an increase
in cardiovascular complications after kidney transplantation
(P = 0.49, log-rank test). A substantial number of early failures
(6 kidney transplant failures and 2 deaths) occurred within
4 months in the group ATG. Four recipients presented a
vascular complication (without rejection), one had an
acute pyelonephritis, and the last one, a multifactorialAdjusted HR 95% CI P
3.1 1.22-7.85 0.017
1 0.97-1.03 0.927
2.02 0.88-4.66 0.097
6.05 0.74-49.44 0.093
0.85 0.23-3.12 0.804
1.48 0.45-4.9 0.517
0.63 0.24-1.65 0.351
1.36 0.66-2.82 0.405
1.07 0.43-2.64 0.891
1.56 0.58-4.22 0.38
1.58 0.73-3.42 0.242
0.17 0.02-1.46 0.107
3.33 1.44-7.7 0.005
1.88 0.96-3.68 0.067
0.13 0.02-1.06 0.057
3.22 1.3-7.95 0.011
survival was obtained using a backward procedure.
of class II anti-HLA antibodies and recipient CMV status.
TABLE 4.
Cause of death according to type of induction therapy
Anti–IL-2R ATG Total
(n = 56) (n = 72) (128)
Infections 2 4 6
Cardiovascular diseases 1 11 12
Stroke 1 2 3
Myocardial infarction or ischemia 0 2 2
Mesenteric infarction 0 1 1
Cardiac failure 0 3 3
Cardiac arrest (undetermined cause) 0 3 3
Cancer 1 2 3
Others 3 3 6
All causes 7 20 27
6 Transplantation DIRECT ■ 2018 www.transplantationdirect.comcause with a posttransplantation serum creatinine always
above 300 μmol/L.Anti-Neu5Gc and Anti-Gal antibodies
Antithymocyte globulin can induce anti-Neu5Gc7 that is
able to interact with diet-derived Neu5Gc present on graft
and patient endothelial cells.6,8 In contrast to ATG,6 mass
spectrometry analysis did not show evidence of the presence
of Neu5Gc on Basilimax (Table S1 http://links.lww.com/
TXD/A74). The levels of anti-Neu5Gc were thus measured
in a subgroup of patients with available sera at 3 different
time points: at the day of the kidney graft before induction
(designated as month 0, M0), as well as at 12 (M12) and
36 (M36) months after the kidney graft (time points chosen
in agreement with previous data showing a late response with
roughly similar IS6). Eleven of them received ATG and 14 re-
ceived anti-IL-2R as induction of their kidney graft. None of
the patients in the ATG group and 2 in the anti-IL-2R group
developed antidonor antibodies after kidney graft. Figure S4
http://links.lww.com/TXD/A72 shows no difference in anti-
Neu5Gc and anti-Gal IgG antibodies compared at M0, M12,
and M36 between the patients having received ATG or anti–
IL-2R induction. Also, there was no difference in the changes
of the level of antibodies before and after induction of each
patient (paired test) at each time point, whatever the nature
of the kidney graft induction.
Finally, despite similar levels of overall anti-Neu5Gc IgG
after induction, we examined a possible shift in the repertoire
of elicited anti-Neu5Gc IgG antibodies compared with the
patterns observed for such preexisting antibodies using a
unique sialoglycan microarray. Figure S5 http://links.lww.
com/TXD/A73 provides a comprehensive overview of the
shift in recognition patterns of anti-Neu5Gc IgG after induc-
tion treatment (see also Supplementary File on Array Data
http://links.lww.com/TXD/A76). Most ATG-treated patients
(8/11) had an increased fold-change in antibodies levels
against some array glycans, whereas in anti–IL-2R-treated
patients, antibodies levels increased (7/14) or decreased (7/14)
(Figure S5A-B http://links.lww.com/TXD/A73). Details of the
new-Neu5Gc epitope recognized are given in the legend of
Figure S5 http://links.lww.com/TXD/A73. Despite all being
oriented toward a more vigorous and diversified response
against Neu5Gc in ATG induction, none of the trends be-
tween the ATG and the anti-IL-2R groups were significant.DISCUSSION
To the best of our knowledge, so far, there has been no
study sustaining a clear recommendation as to the immuno-
suppressive treatment strategy for such recipients, that is, al-
ready exposed to long-term IS treatment at the time of their
kidney transplantation. In one study on the outcome of kid-
ney transplantation after NRT,5 induction therapy was not
associated with improved patient survival andwas even asso-
ciated with inferior patient survival in the subset of patients
with kidney graft after liver transplantation. Similarly, in a
recent article aimed at assessing the impact of repeat mis-
matches in kidney transplantations, induction therapy was
also not found to affect kidney graft survival.12 However,
the cohort analyzed in this article markedly differs from our
own because it included up to 25% of patients who had re-
ceived a simultaneous kidney/NRT (kidney/pancreas, kidney/
liver, etc) as the first graft. In another study showing no differ-
ence in kidney graft survival between primary, repeat, and kid-
ney after NRT, induction therapy was also not found to be a
significant determinant of graft outcome.13 However, in these
aforementioned studies, there was no direct comparison of the
impact of ATG versus anti–IL-2R induction therapy on graft
survival. The 2 groups of patients in our study differed by sev-
eral variables classically associated with lower survival due to
the policy of preferential indication of ATG induction in
patients at high immunological risks. However, the multi-
variate analysis has taken into account those variables
and confirms that patients having received induction by
ATG for their kidney transplantation have higher risk of
graft loss or of death compared with those who had an
anti–IL-2R induction. The difference remains similar when
the patients having received ATG before the availability of
anti–IL-2R Abs were excluded and only patients grafted in
the same period were compared (Figure S1 http://links.
lww.com/TXD/A69). Moreover, this conclusion was em-
phasized by the propensity score analysis, which strongly
suggests that the lower survival of ATG treated patients
was not only due to baseline differences and that ATG itself
also contributed to the difference observed. Finally, the
poor outcome associated with ATG induction therapy ap-
pears to be limited to kidney recipients after NRT. In one
of our studies based on our DIVAT database, we analyzed
a large cohort of patients having received first and second
kidney grafts and found that induction therapy with de-
pleting antibodies (ATG or anti-CD3) was not associated
with different risk of graft failure compared with nonde-
pleting antibodies (anti–IL-2R).14 Unlike recipients of kid-
ney graft after a NRT, patients with a second kidney graft
have rejected their first kidney graft and are no longer under
maintenance IS at the time of the second graft, we hypothe-
size that stronger induction with ATG might be useful for
these patients.
The analysis of possible causes of patient and kidney graft
losses did not provide a direct answer to explain the lower graft
survival in theATGgroup.Wedid not find a significant increase
in the frequencies of severe infectious diseases andmalignancies
in the ATG group, perhaps larger cohort studies are needed to
determine whether ATG causes overimmunosuppression in this
type of patients. Similarly, cardiovascular complications were
also not different between the 2 groups (Figure S3D http://
links.lww.com/TXD/A71), despite more frequent early car-
diovascular complications in the ATG group. Diet-derived
© 2018 Wolters Kluwer Mai et al 7Neu5Gc can accumulate in endothelial cells of humans despite
the loss mutation of the CMAH gene15,16 and thus patients
having been exposed to a higher or different response against
Neu5Gc may suffer from vascular inflammation.8,17 Further-
more, if basal preexisting anti-Neu5Gc IgGs (diet-induced)
are likely not detrimental to human ECs owing to their
presence in the sera of most of healthy individuals, ATG-
elicited antibodies are able to recognize new epitopes of
Neu5Gc at higher levels, as evidenced here and in other
clinical contexts.18 Indeed, although ATG contains anti-
genic Neu5Gc and Gal. In contrast, the chimeric anti–IL-2R
used in our patients (basiliximab) is prepared in Chinese
hamster ovary cells and did not exhibit detectable Neu5Gc
by mass spectrometry (Table S1 http://links.lww.com/TXD/
A74). A detailed array study of the immune response to a va-
riety of Neu5Gc epitopes after ATG and Basilimax induction
and the shift of anti-Neu5Gc IgG repertoire for new epitopes
were thus analyzed in a subgroup of patients with enough
prekidney and postkidney transplantation sera available for
the tests. The fine analysis of the anti-Neu5Gc IgG repertoire
on the sialoglycan arrays also showed that some newly recog-
nized specificities (red score in Figure S5A http://links.lww.
com/TXD/A73) were indeed strongly increased, whereas the
global ELISA-based assessment of the anti-Neu5Gc IgGs
levels could not detect these changes. However, whether a
shift in the antibody repertoire againstNeu5Gc epitopes after
ATG induction contributes to the difference in clinical out-
come, particularly to the incidence of early cardiovascular
complications, remains speculative and requires similar
investigations using sialoglycan microarray in a much
larger cohort.
Despite several limitations, especially the small number of
patients and the heterogeneity of the study population, our
study suggests that ATG induction after a kidney transplanta-
tion in recipients already under maintenance immunosup-
pressive treatment for a previous nonrenal graft should be
used cautiously. Our report also urges randomized prospec-
tive studies not only to compare anti–IL-2R to ATG treat-
ment but also to compare induction with no induction to
determine whether induction therapies are beneficial to
these patients.REFERENCES
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